Payload Information

General Information of This Payload
Payload ID
PAY0WKBCR
Name
PNU-159682
Synonyms
PNU-159682; 202350-68-3; UNII-CQ5A9ZNT7C; CQ5A9ZNT7C; PNU159682; PNU 159682; (8S,10S)-6,8,11-Trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-10-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-7,8,9,10-tetrahydrotetracene-5,12-dione; (7S,9S)-6,9,11-Trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-7-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-8,10-dihydro-7H-tetracene-5,12-dione; (8S,10S)-7,8,9,10-Tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-10-(((1S,3R,4aS,9S,9aR,10aS)-octahydro-9-methoxy-1-methyl-1H-pyrano(4',3':4,5)oxazolo(2,3-C)(1,4)oxazin-3-yl)oxy)-5,12-naphthacenedione; 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-10-(((1S,3R,4aS,9S,9aR,10aS)-octahydro-9-methoxy-1-methyl-1H-pyrano(4',3':4,5)oxazolo(2,3-C)(1,4)oxazin-3-yl)oxy)-, (8S,10S)-; (8S,10S)-7,8,9,10-Tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-10-[[(1S,3R,4aS,9S,9aR,10aS)-octahydro-9-methoxy-1-methyl-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl]oxy]-5,12-naphthacenedione; SCHEMBL3801318; CHEMBL4777727; SLURUCSFDHKXFR-WWMWMSKMSA-N; EX-A3364; CS-3298; BP-29359; HY-16700; MS-30920; A903771; (8S,10S)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-10-{[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.0,tridecan-4-yl]oxy}-5,7,8,9,10,12-hexahydrotetracene-5,12-dione; (8S,10S)-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-{[(1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5] [1,3] oxazolo[2,3-c][1,4]oxazin-3-yl]oxy}-7,8,9,10-tetrahydrotetracene-5,12-dione; (8S,10S)-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-{[(1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5][1,3]oxazolo[2,3-c][1,4]oxazin-3-yl]oxy}-7,8,9,10-tetrahydrotetracene-5,12-dione
   Click to Show/Hide
Target(s) DNA topoisomerase 2-alpha (TOP2A)
 Target Info 
Structure
Formula
C32H35NO13
Isosmiles
C[C@H]1[C@@H]2[C@H](C[C@@H](O1)O[C@H]3C[C@@](CC4=C3C(=C5C(=C4O)C(=O)C6=C(C5=O)C(=CC=C6)OC)O)(C(=O)CO)O)N7CCO[C@@H]([C@H]7O2)OC
PubChem CID
9874188
InChI
InChI=1S/C32H35NO13/c1-13-29-16(33-7-8-43-31(42-3)30(33)46-29)9-20(44-13)45-18-11-32(40,19(35)12-34)10-15-22(18)28(39)24-23(26(15)37)25(36)14-5-4-6-17(41-2)21(14)27(24)38/h4-6,13,16,18,20,29-31,34,37,39-40H,7-12H2,1-3H3/t13-,16-,18-,20-,29+,30+,31-,32-/m0/s1
InChIKey
SLURUCSFDHKXFR-WWMWMSKMSA-N
IUPAC Name
(7S,9S)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-7-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-8,10-dihydro-7H-tetracene-5,12-dione
Pharmaceutical Properties
Molecule Weight
641.6
Polar area
191
Complexity
1200
xlogp Value
2.4
Heavy Count
46
Rot Bonds
6
Hbond acc
14
Hbond Donor
4
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
SOT-102 [Phase 1/2]
 ADC Info 
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT05525286  Phase Status Phase 1
Clinical Description
A multicentric phase 1/2 trial to evaluate the safety and efficacy of SOT102 as monotherapy and in combination with standard of care treatment in patients with gastric and pancreatic adenocarcinoma.
HuXBR1-402-G5-PNU [Clinical candidate]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [2]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
1.27 ng/mL
Positive ROR1 expression (ROR1+++/++)
Method Description
Cell lines obtained from ATCC were serum starved for 16 hours and reintroduced to full serum media supplemented huXBR1-402-G5-PNU for 72 hours. Viability was measured by using MTS assays, and relative light unit (RLU) values for each dose were generated after 72 hours of treatment in 2 independent experiments.
In Vitro Model Childhood B acute lymphoblastic leukemia Kasumi-2 cells CVCL_0590
Experiment 2 Reporting the Activity Date of This ADC [2]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
75.68 ng/mL
Positive ROR1 expression (ROR1+++/++)
Method Description
Cell lines obtained from ATCC were serum starved for 16 hours and reintroduced to full serum media supplemented huXBR1-402-G5-PNU for 72 hours. Viability was measured by using MTS assays, and relative light unit (RLU) values for each dose were generated after 72 hours of treatment in 2 independent experiments.
In Vitro Model Childhood B acute lymphoblastic leukemia 697 cells CVCL_0079
HuIgG1-19 [Investigative]
 ADC Info 
Discovered Using Patient-derived Xenograft Model
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [3]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 13.33% (Day 30 Positive CD46 expression (CD46 +++/++)
Method Description
In vivo efficacy of PNU-conjugated ADCs in NSCLC LU253 PDX subcutaneous models in NOD/SCID mice. A single dose of 1.0 mg/kg HuIgG1-19 ADC.
In Vivo Model Non-small cell lung cancer PDX model (PDX: LU253 PDX)
Experiment 2 Reporting the Activity Date of This ADC [3]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 21.34% (Day 15) Positive CD46 expression (CD46 +++/++)
Method Description
In vivo efficacy of PNU-conjugated ADCs in colorectal CR188 PDX subcutaneous models in NOD/SCID mice. A single dose of 1.0 mg/kg HuIgG1-19 ADC.
In Vivo Model Colorectal cancer PDX model (PDX: CR188 PDX)
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [3]
Efficacy Data Half Maximal Effective Concentration (EC50) > 3.00 nM Positive CD46 expression (CD46 +++/++)
Method Description
Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
In Vitro Model Uterine sarcoma MES-SA cells CVCL_1404
Experiment 2 Reporting the Activity Date of This ADC [3]
Efficacy Data Half Maximal Effective Concentration (EC50)
3.80 nM
Positive CD46 expression (CD46 +++/++)
Method Description
Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
In Vitro Model Normal HEK293T cells CVCL_0063
hCD46-19 [Investigative]
 ADC Info 
Discovered Using Patient-derived Xenograft Model
Click To Hide/Show 4 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [3]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 52.34% (Day 30) Positive CD46 expression (CD46 +++/++)
Method Description
In vivo efficacy of PNU-conjugated ADCs in NSCLC LU253 PDX subcutaneous models in NOD/SCID mice. A single dose of 0.5 mg/kg hCD46-19 ADC.
In Vivo Model Non-small cell lung cancer PDX model (PDX: LU253 PDX)
Experiment 2 Reporting the Activity Date of This ADC [3]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 77.34% (Day 30) Positive CD46 expression (CD46 +++/++)
Method Description
In vivo efficacy of PNU-conjugated ADCs in colorectal CR188 PDX subcutaneous models in NOD/SCID mice. A single dose of 0.5 mg/kg hCD46-19 ADC.
In Vivo Model Colorectal cancer PDX model (PDX: CR188 PDX)
Experiment 3 Reporting the Activity Date of This ADC [3]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 86.67% (Day 30) Positive CD46 expression (CD46 +++/++)
Method Description
In vivo efficacy of PNU-conjugated ADCs in colorectal CR188 PDX subcutaneous models in NOD/SCID mice. A single dose of 1.0 mg/kg hCD46-19 ADC.
In Vivo Model Colorectal cancer PDX model (PDX: CR188 PDX)
Experiment 4 Reporting the Activity Date of This ADC [3]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 90.48% (Day 30) Positive CD46 expression (CD46 +++/++)
Method Description
In vivo efficacy of PNU-conjugated ADCs in NSCLC LU253 PDX subcutaneous models in NOD/SCID mice. A single dose of 1.0 mg/kg hCD46-19 ADC.
In Vivo Model Non-small cell lung cancer PDX model (PDX: LU253 PDX)
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [3]
Efficacy Data Half Maximal Effective Concentration (EC50)
47.00 pM
Positive CD46 expression (CD46 +++/++)
Method Description
Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
In Vitro Model Normal HEK293T cells CVCL_0063
Experiment 2 Reporting the Activity Date of This ADC [3]
Efficacy Data Half Maximal Effective Concentration (EC50) > 3.00 nM Positive CD46 expression (CD46 +++/++)
Method Description
Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
In Vitro Model Uterine sarcoma MES-SA cells CVCL_1404
Trastuzumab-PNUEDAGly5 [Investigative]
 ADC Info 
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [4]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% (Day 60) Positive HER2 expression (HER2 +++/++)
Method Description
1,000,000 EMT6 mouse breast cancer cells expressing human HER-2 previously determined to be suitable for in vivo growth, were implanted into theright mammary fat pads of female Balb/c mice. Animals were treated onthe same day (day 13) and 7 days later (day 20) byintravenous injection of the reference ADC Kadcyla (15 mg/kg), Trastuzumab-PNU-EDA-Glys (1 mg/kg) or vehicle control.

   Click to Show/Hide
In Vivo Model EMT6 CDX model (Expressing hHER2)
In Vitro Model Mammary gland malignant neoplasms EMT6 cells (High HER2 expression) CVCL_1923
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [6]
Efficacy Data Half Maximal Effective Concentration (EC50)
6.90 ng/mL
High CD30 expression (CD30 +++)
Method Description
Dose response of the cytotoxic effects of the indicated ADCs on human Non-Hodgkin lymphoma cell line Karpas-299, and on human Hodgkin lymphoma cell line L428 cells.
In Vitro Model ALK-positive anaplastic large cell lymphoma Karpas-299 cells CVCL_1324
Experiment 2 Reporting the Activity Date of This ADC [6]
Efficacy Data Half Maximal Effective Concentration (EC50) < 10.00 ug/mL Low CD30 expression (CD30 +)
Method Description
Dose response of the cytotoxic effects of the indicated ADCs on human Non-Hodgkin lymphoma cell line Karpas-299, and on human Hodgkin lymphoma cell line L428 cells.
In Vitro Model Hodgkin lymphoma L-428 cells CVCL_1361
Tras-Gly5-EDA-Pnu [Investigative]
 ADC Info 
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [5]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% (Day 26) High HER2 expression (HER2+++; 170,000 HER2 molecules/cell)
Method Description
JIMT-1 cells were transplanted subcutaneously into CB17.SCID mice and tumors were allowed to grow to a volume of 100-150 mm3. Mice were then treated intravenously 3 times weekly with the 1 mg/kg ADC preparations.
In Vivo Model Trastuzumab-resistant breast cancer CDX model
In Vitro Model Breast ductal carcinoma JIMT-1 cells CVCL_2077
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
2.70 ng/mL
High HER2 expression (HER2+++; 694,000 HER2 molecules/cell)
Method Description
Briefly, cells were plated on 96-well plates in 75 uL growth medium and grown at 37°C in a humidified incubator in a 7.5% CO2 atmosphere. After one day incubation, 25 uL of 3.5-fold serial dilutions of each ADC in growth medium were added, typically resulting in final ADC concentrations from 20 ug/mL to 0.02 ng/mL.
In Vitro Model Breast adenocarcinoma SK-BR-3 cells CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
14.70 ng/mL
Moderate HER2 expression (HER2++; 32,000 HER2 molecules/cell)
Method Description
Briefly, cells were plated on 96-well plates in 75 uL growth medium and grown at 37°C in a humidified incubator in a 7.5% CO2 atmosphere. After one day incubation, 25 uL of 3.5-fold serial dilutions of each ADC in growth medium were added, typically resulting in final ADC concentrations from 20 ug/mL to 0.02 ng/mL.
In Vitro Model Invasive breast carcinoma T-47D cells CVCL_0553
CAC10-Gly5-PNU [Investigative]
 ADC Info 
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [5]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% (Day 16) High CD30 expression (CD30+++)
Method Description
CD30 Karpas-299 cells were either transplanted subcutaneously into NSG, or into CB17.SCID mice. Mice were treated intravenously 3 times weekly with 1 mg/kg preparations, beginning one day post randomization, when the tumors had reached a size ranging between 100 and 150 mm3.
In Vivo Model Non-Hodgkin's lymphoma CDX model
In Vitro Model ALK-positive anaplastic large cell lymphoma Karpas-299 cells CVCL_1324
Experiment 2 Reporting the Activity Date of This ADC [5]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% (Day 14) High CD30 expression (CD30+++)
Method Description
CD30 Karpas-299 cells were either transplanted subcutaneously into NSG, or into CB17.SCID mice. Mice were treated intravenously 3 times weekly with 1 mg/kg preparations, beginning one day post randomization, when the tumors had reached a size ranging between 100 and 150 mm3.
In Vivo Model Non-Hodgkin's lymphoma CDX model
In Vitro Model ALK-positive anaplastic large cell lymphoma Karpas-299 cells CVCL_1324
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
1.80 ng/mL
High CD30 expression (CD30+++)
Method Description
Briefly, cells were plated on 96-well plates in 75 uL growth medium and grown at 37°C in a humidified incubator in a 7.5% CO2 atmosphere. After one day incubation, 25 uL of 3.5-fold serial dilutions of each ADC in growth medium were added, typically resulting in final ADC concentrations from 20 ug/mL to 0.02 ng/mL.
In Vitro Model ALK-positive anaplastic large cell lymphoma Karpas-299 cells CVCL_1324
Experiment 2 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
4.80 ng/mL
Negative CD30 expression (CD30-)
Method Description
Briefly, cells were plated on 96-well plates in 75 uL growth medium and grown at 37°C in a humidified incubator in a 7.5% CO2 atmosphere. After one day incubation, 25 uL of 3.5-fold serial dilutions of each ADC in growth medium were added, typically resulting in final ADC concentrations from 20 ug/mL to 0.02 ng/mL.
In Vitro Model B acute lymphoblastic leukemia Reh cells CVCL_1650
Tras-Gly3-Vakl-Cit-PAB-PNU-159682 [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.24 ng/mL
High HER2 expression (HER2+++; 694,000 HER2 molecules/cell)
Method Description
Briefly, cells were plated on 96-well plates in 75 uL growth medium and grown at 37°C in a humidified incubator in a 7.5% CO2 atmosphere. After one day incubation, 25 uL of 3.5-fold serial dilutions of each ADC in growth medium were added, typically resulting in final ADC concentrations from 20 ug/mL to 0.02 ng/mL.
In Vitro Model Breast adenocarcinoma SK-BR-3 cells CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
12.00 ng/mL
Moderate HER2 expression (HER2++; 32,000 HER2 molecules/cell)
Method Description
Briefly, cells were plated on 96-well plates in 75 uL growth medium and grown at 37°C in a humidified incubator in a 7.5% CO2 atmosphere. After one day incubation, 25 uL of 3.5-fold serial dilutions of each ADC in growth medium were added, typically resulting in final ADC concentrations from 20 ug/mL to 0.02 ng/mL.
In Vitro Model Invasive breast carcinoma T-47D cells CVCL_0553
hCD46-29 [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [3]
Efficacy Data Half Maximal Effective Concentration (EC50)
41.00 pM
Positive CD46 expression (CD46 +++/++)
Method Description
Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
In Vitro Model Uterine sarcoma MES-SA cells CVCL_1404
Experiment 2 Reporting the Activity Date of This ADC [3]
Efficacy Data Half Maximal Effective Concentration (EC50)
1.60 nM
Positive CD46 expression (CD46 +++/++)
Method Description
Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
In Vitro Model Normal HEK293T cells CVCL_0063
hCD46-25 [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [3]
Efficacy Data Half Maximal Effective Concentration (EC50)
95.00 pM
Positive CD46 expression (CD46 +++/++)
Method Description
Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
In Vitro Model Uterine sarcoma MES-SA cells CVCL_1404
Experiment 2 Reporting the Activity Date of This ADC [3]
Efficacy Data Half Maximal Effective Concentration (EC50)
5.19 nM
Positive CD46 expression (CD46 +++/++)
Method Description
Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
In Vitro Model Normal HEK293T cells CVCL_0063
HuIgG1-26 [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [3]
Efficacy Data Half Maximal Effective Concentration (EC50)
1000 pM
Positive CD46 expression (CD46 +++/++)
Method Description
Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
In Vitro Model Uterine sarcoma MES-SA cells CVCL_1404
Experiment 2 Reporting the Activity Date of This ADC [3]
Efficacy Data Half Maximal Effective Concentration (EC50)
1.10 nM
Positive CD46 expression (CD46 +++/++)
Method Description
Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
In Vitro Model Normal HEK293T cells CVCL_0063
HuIgG1-25 [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [3]
Efficacy Data Half Maximal Effective Concentration (EC50) > 1000 pM Positive CD46 expression (CD46 +++/++)
Method Description
Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
In Vitro Model Normal HEK293T cells CVCL_0063
Experiment 2 Reporting the Activity Date of This ADC [3]
Efficacy Data Half Maximal Effective Concentration (EC50) > 3.00 nM Positive CD46 expression (CD46 +++/++)
Method Description
Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
In Vitro Model Uterine sarcoma MES-SA cells CVCL_1404
hCD46-26 [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [3]
Efficacy Data Half Maximal Effective Concentration (EC50)
0.10 nM
Positive CD46 expression (CD46 +++/++)
Method Description
Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
In Vitro Model Uterine sarcoma MES-SA cells CVCL_1404
Experiment 2 Reporting the Activity Date of This ADC [3]
Efficacy Data Half Maximal Effective Concentration (EC50)
0.19 nM
Positive CD46 expression (CD46 +++/++)
Method Description
Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
In Vitro Model Normal HEK293T cells CVCL_0063
HuIgG1-29 [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [3]
Efficacy Data Half Maximal Effective Concentration (EC50)
1.40 nM
Positive CD46 expression (CD46 +++/++)
Method Description
Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
In Vitro Model Uterine sarcoma MES-SA cells CVCL_1404
Experiment 2 Reporting the Activity Date of This ADC [3]
Efficacy Data Half Maximal Effective Concentration (EC50)
2.00 nM
Positive CD46 expression (CD46 +++/++)
Method Description
Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
In Vitro Model Normal HEK293T cells CVCL_0063
Brentuximab-PNUEDAGly5 [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [4]
Efficacy Data Half Maximal Effective Concentration (EC50)
4.80 ng/mL
High HER2 expression (HER2 +++)
Method Description
For this, cells were plated on 96 well plates in 100 ul DMEM/10% FCS at adensity of 104 cells per well and assays were performed.
In Vitro Model Breast adenocarcinoma SK-BR-3 cells CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC [4]
Efficacy Data Half Maximal Effective Concentration (EC50)
11.00 ng/mL
Low HER2 expression (HER2 +)
Method Description
For this, cells were plated on 96 well plates in 100 ul DMEM/10% FCS at adensity of 104 cells per well and assays were performed.
In Vitro Model Invasive breast carcinoma T-47D cells CVCL_0553
References
Ref 1 A Multicentric Phase 1/2 Trial to Evaluate the Safety and Efficacy of SOT102 as Monotherapy and in Combination With Standard of Care Treatment in Patients With Gastric and Pancreatic Adenocarcinoma, NCT05525286
Ref 2 The ROR1 antibody-drug conjugate huXBR1-402-G5-PNU effectively targets ROR1+ leukemia. Blood Adv. 2021 Aug 24;5(16):3152-3162.
Ref 3 Evaluation of PNU-159682 antibody drug conjugates (ADCs). Bioorg Med Chem Lett. 2020 Dec 15;30(24):127640. doi: 10.1016/j.bmcl.2020.127640. Epub 2020 Oct 28.
Ref 4 Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof; 2017-10-19.
Ref 5 Highly Potent, Anthracycline-based Antibody-Drug Conjugates Generated by Enzymatic, Site-specific Conjugation. Mol Cancer Ther. 2017 May;16(5):879-892.
Ref 6 Binding protein drug conjugates comprising anthracycline derivatives; 2016-06-30.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.